Pharmacist-managed chronic obstructive pulmonary disease screening in a community setting

Journal of the American Pharmacists Association

Volumn 52, Issue 5, 2012, Pages

  Fuller, Leah ^a,b   Conrad, Wayne F ^b   Heaton, Pamela C ^b   Panos, Ralph ^c   Eschenbacher, William ^c   Frede, Stacey M ^a  

^a Kroger Patient Care Center   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic obstructive pulmonary disease; Community pharmacy; Health screening; Smoking cessation; Spirometry

Indexed keywords

BRONCHODILATING AGENT; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; MOMETASONE FUROATE; MONTELUKAST; SALBUTAMOL; ZAFIRLUKAST;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; AWARENESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENERAL PRACTITIONER; HUMAN; LIMIT OF DETECTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COUNSELING; PHARMACIST; PHARMACY; POSITIVE END EXPIRATORY PRESSURE; PROSPECTIVE STUDY; QUESTIONNAIRE; RESPIRATORY AIRFLOW; RISK FACTOR; SCREENING TEST; SEMI STRUCTURED INTERVIEW; SMOKING; SMOKING CESSATION PROGRAM; SPIROMETER; SPIROMETRY; AGED; COMORBIDITY; MASS SCREENING; METHODOLOGY; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; SMOKING CESSATION;

ADULT; AGED; COMMUNITY PHARMACY SERVICES; COMORBIDITY; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION; SPIROMETRY;

MLCS; MLOWN;

EID: 84874434840     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2012.11100     Document Type: Article

References (41)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2009. Accessed at www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2003, December 10, 2009.
2. Carmona RH. The health consequences of smoking: a report of the Surgeon General. Washington, DC: Department of Health & Human Services; 2004.
3. National Heart, Lung, and Blood Institute. Morbidity and morality: 2007 chartbook on cardiovascular, lung, and blood disease. Bethesda, MD: National Heart, Lung, and Blood Institute; 2009.
4. Pleis JR, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey, 2007. Vital Health Stat 10. 2009;240:1-159.
5. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000;160:1683-9.
6. American Thoracic Society. COPD guidelines (2004): standards for the diagnosis and management of patients with COPD. Accessed at www.thoracic.org/ clinical/copd-guidelines/resources/copddoc.pdf, September 12, 2009.
7. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax. 2006;61:869-73.
8. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336:598-600.
9. Wilt TJ, Niewoehner D, Kane RL, et al. Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res. 2007;9:21-32.
10. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994;272:1497-1505.
11. Burchfiel CM, Marcus EB, Curb JD, et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med. 1995;151:1778-85.
12. Duong-Quy S, Hua-Huy T, Mai-Huu-Thanh B, et al. Early detection of smoking-related chronic obstructive pulmonary disease in Vietnam. Rev Mal Respir. 2009;26:267-74.
13. DeJong SR, Veltman RH. The effectiveness of a CNS-led com-munity- based COPD screening and intervention program. Clin Nurse Spec. 2004;18:72-9.
14. Bednarek M, Plywaczewski R, Gorecka D, et al. Early detection of COPD in smokers from Warsaw using spirometric screening. Pneumonol Alergol Pol. 2002;70:139-47.
15. Geijer RM, Sachs AP, Hoes AW, et al. Prevalence of undetected persistent airflow obstruction in male smokers 40-65 years old. Fam Pract. 2005;22:485-9.
16. Tinkelman DG, Price D, Nordyke RJ, Halbert RJ. COPD screening efforts in primary care: what is the yield? Prim Care Respir J. 2007;16:41-8.
17. Vandevoorde J, Verbanck S, Gijssels L, et al. Early detection of COPD: a case finding study in general practice. Respir Med. 2007;101:525-30.
18. Stratelis G, Jakobsson P, Molstad S, Zetterstrom O. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. Br J Gen Pract. 2004;54:201-6.
19. Stav D, Raz M. Prevalence of chronic obstructive pulmonary disease among smokers aged 45 and up in Israel. Isr Med Assoc J. 2007;9:800-2.
20. Zielinski J, Bednarek M. Know the age of your lung study group: early detection of COPD in a high-risk population using spirometric screening. Chest. 2001;119:731-6.
21. Tovar JM, Gums JG. Monitoring pulmonary function in asthma and COPD: point-of-care testing. Ann Pharmacother. 2004;38:126-33.
22. Burton MA, Burton DL, Simpson MD, et al. Respiratory function testing: the impact of respiratory scientists on the training and support of primary health care providers. Respirology. 2004;9:260-4.
23. Castillo D, Guayta R, Giner J, et al. COPD case finding by spirometry in high-risk customers of urban community pharmacies: a pilot study. Respir Med. 2009;103:839-45.
24. Stratton TP, Williams RG, Meine KL. Developing a mobile pharmacist-conducted wellness clinic for rural Montana communities. J Am Pharm Assoc. 2005;45:390-9.
25. Mann RP, Zaiken K. Management of chronic obstructive pulmonary disease by pharmacists in an internal medicine department. Am J Health Syst Pharm. 2009;66:890-3.
26. Weinberger M, Murray MD, Marrero DG, et al. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA. 2002;288:1594-1602.
27. American Pharmacists Association Foundation. White paper on expanding the role of pharmacists in chronic obstructive pulmonary disease. J Am Pharm Assoc. 2011;51:203-11.
28. Egervary A. No 'I' in 'Pharmacy'. Pharmacy Today. 2008;14:42-4.
29. Martinez FJ, Raczek AE, Seifer FD, at al. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD. 2008;5(2):85-95.
30. Miller MR, Hankinson J, Brusasco V, et al. ATS/ERS Task Force: standardization of lung function testing: standardization of spirometry. Eur Respir J. 2005;26:319-38.
31. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179-87.
32. Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63:1046-51.
33. Morris JF, Temple W. Short report: spirometric "lung age" estimation for motivating smoking cessation. Prev Med. 1985;14:655-62.
34. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1984-1994. Arch Intern Med. 2000;160:1683-9.
35. Eaton T, Withy S, Garrett JE, et al. Spirometry in primary care practice. Chest. 1999;116:416-23.
36. Walters JA, Hansen EC, Johns DP, et al. A mixed methods study to compare models of spirometry delivery in primary care for patients at risk of COPD. Thorax. 2008;63:408-14.
37. Summaries for patients. Screening for chronic obstructive pulmonary disease: U.S. Preventive Services Task Force recommendations. Ann Intern Med. 2008;148:I46.
38. Lin K, Watkins B, Johnson T, et al. U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;148:535-43.
39. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet. 2009;374:721-32.
40. Enright PL, Crapo RO. Controversies in the use of spirometry for early recognition and diagnosis of chronic obstructive pulmonary disease in cigarette smokers. Clin Chest Med. 2000;21:645-52.
41. Cawley MJ, Pacitti RJ, Keenan DP. Reaping the rewards of a pharmacist-run spirometry clinic. Pharmacy Purchasing & Products. 2010;7:24.